We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.
- Authors
Delbaldo, Catherine; Faivre, Sandrine; Dreyer, Chantal; Raymond, Eric
- Abstract
Based on preclinical data available in the RIP1-Tag2 transgenic mouse model, sunitinib is an inhibitor of angiogenesis in pancreatic neuroendocrine tumors blocking vascular endothelial growth factor receptors and platelet-derived growth factor receptors in endothelial cells and pericytes, respectively. Evidence of objective response in phase I trials justified the initiation of a large phase II/III program using sunitinib in patients with advanced/metastatic well-differentiated pancreatic neuroendocrine tumors. In the phase II study, sunitinib showed potent antitumor activity and a safe toxicity profile. In a recent double-blind placebo-controlled randomized phase III trial, sunitinib doubled the progression-free survival of patients, induced objective responses, and reduced the risk of death of patients with advanced/metastatic well-differentiated tumors. These data allowed the approval of sunitinib in several countries including Europe and the United States of America. These recent data provide hope for patients with well-differentiated pancreatic neuroendocrine tumors and will change standards of care in this disease.
- Publication
Therapeutic Advances in Medical Oncology, 2012, Vol 4, Issue 1, p9
- ISSN
1758-8340
- Publication type
Article
- DOI
10.1177/1758834011428147